Spravato Treatment Center

Spravato (esketamine) is lifesaving for people with severe depression who do not respond to other depression treatments. About 30 to 40% of patients with depression fail to respond to first-line treatments including oral antidepressant medications of all classes (selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), etc.) and/or psychotherapy. We can offer Spravato treatment for patients whose depression has not responded to other therapies, described as the “Breakthrough in Depression Treatment in 50 Years.”  Spravato is now an FDA approved treatment. NeuroPsych Wellness Center, PC is proud to have helped prove the efficacy of this breakthrough treatment and to be one of the first to use the newly available groundbreaking treatment.

As of March 2023, our office has given over 5,000 nasal spray treatments of ketamine or esketamine to patients. Our experience is unparalleled. Spravato is the new brand name for esketamine that comes in ready to use nasal spray. It was approved by the FDA in March 2019 for patients with treatment resistant depression, in conjunction with an oral antidepressant. The FDA requires that Spravato treatment takes place only at approved treatment centers. By law, it cannot be prescribed for home use. The treatment is done as an outpatient in the privacy of our offices. The reason antidepressants may not work for everyone is that they target just a few of the brain’s chemical transmitter systems, such as serotonin, norepinephrine, and dopamine.

Spravato is NMDA receptor antagonist for treatment resistant depression. NMDA receptors modulate glutamate. Spravato treatment at NeuroPsych Wellness Center, PC is covered by your insurance. Spravato treatment at our clinic is provided and monitored by Clinicians not technicians.

  1. What is Spravato?
  2. Getting Started on Spravato
  3. Patient Stories
  4. Proven effective for depressive symptoms in adults with major depressive disorder (MDD) with suicidal thoughts or actions (MDSI).